Following the US approval of the first CGRP small molecule receptor antagonist, ubrogepant, for the acute treatment of migraine, Peter Goadsby looks at the potential impact of targeting the CGRP pathway for both prevention and treatment of migraine.
CGRP therapies in acute migraine
Following the US approval of the first CGRP small molecule receptor antagonist, ubrogepant, for the acute treatment of migraine, Peter Goadsby looks at the potential impact of targeting the CGRP pathway for both prevention and treatment of migraine.
0 Comments